Tegaserod

Tegaserod
Clinical data
Trade names	Zelnorm, Zelmac
AHFS/Drugs.com	Monograph
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral
ATC code	A06AX06 (WHO) ;
Legal status
Legal status	US: Usage requires authorization from the FDA;
Pharmacokinetic data
Bioavailability	10%
Protein binding	98%
Metabolism	Gastric and hepatic
Elimination half-life	11 ± 5 hours
Excretion	Fecal and renal
Identifiers
	IUPAC name (2E)-2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide;
CAS Number	145158-71-0 ;
PubChem CID	5362436;
IUPHAR/BPS	226;
DrugBank	DB01079 ;
ChemSpider	10609889 ;
UNII	458VC51857;
KEGG	D02730 ;
ChEMBL	ChEMBL76370 ;
CompTox Dashboard (EPA)	DTXSID6045955 ;
ECHA InfoCard	100.158.793
Chemical and physical data
Formula	C16H23N5O
Molar mass	301.394 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCNC(=N)NN=Cc1c[nH]c2ccc(OC)cc12;
	InChI InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+ ; Key:IKBKZGMPCYNSLU-RGVLZGJSSA-N ;
	(what is this?) (verify)

Tegaserod is a 5-HT₄ agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation.^[1] Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.^[2]

^ "New Data for Zelnorm". Archived from the original on December 9, 2007. Retrieved March 30, 2007.
^ "FDA approves first treatment for women with irritable-bowel syndrome". Food and Drug Administration. Archived from the original on February 5, 2007. Retrieved March 30, 2007.

[1] "New Data for Zelnorm". Archived from the original on December 9, 2007. Retrieved March 30, 2007.

[2] "FDA approves first treatment for women with irritable-bowel syndrome". Food and Drug Administration. Archived from the original on February 5, 2007. Retrieved March 30, 2007.

[1]

[2]